npi-001
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Jun 30, 2020 (NCT04355689)
Timeline
Indications
Mechanism of action
- Unspecified targetAntioxidant
antioxidant
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07290530 | Phase 3 | Jun 30, 2026 | Nacuity Pharmaceuticals, Inc. |
| NCT05994534 | Phase 1/Phase 2 (Phase 2) | Oct 29, 2023 | Nacuity Pharmaceuticals, Inc. |
| NCT04355689 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2020 | Foundation Fighting Blindness, Nacuity Pharmaceuticals, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nacuity Pharmaceuticals, Inc. | For profit | 3 | 3 | 2 | 2020 |
| Foundation Fighting Blindness | Academic/Hospital | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1